Page 3 - Biocon

Cordelia Cruise owner files DRHP, NSEIX inks MoU with CSE, and more

The International Finance Corporation (IFC), a member of the World Bank Group, has signed an agreement to invest $60 million in Motilal Oswal Alternates' India Business Excellence Fund V G

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Biocon opens Rs 4,500-crore qualified institutional placement to repay debt, invest in Biocon Biologics and meet general corporate obligations

F&O picks: Biocon shows strength on charts, adopt Bull Spread: Nandish Shah

F&O strategy: Short-term trend of the Midcp Nifty turned weak, while it is strong for Biocon

Biocon gets CDSCO approval for generic diabetes medication 'Liraglutide'

Biotech firm Biocon on Tuesday said it has received approval from the government authorities for a generic diabetes medication. The company has received approval for its Liraglutide drug substance and its wholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India (CDSCO). The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing. "The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said. India has one of the highest number of people with diabetes globally, with ...

Biocon share price pops 2% on CDSCO nod for diabetes drug; key details here

Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug, which is used in the treatment of type 2 diabetes.

Biocon share rises as arm secures UK MHRA nod for plaque psoriasis drug

Biocon share rose after arm, Biocon Biologics, was granted market authorisation in the UK for Yesintek, a biosimilar of Ustekinumab, from the Medicines and Healthcare products Regulatory Agency (MHRA)

Biocon Biologics gets six-month extension of insulin supply in Malaysia

Biocon Biologics to continue insulin supply in Malaysia through October 2025 as MoH extends existing contract under partnership with Duopharma and Biocon Sdn. Bhd.

Biocon shares gain 2% as Japan partner launches Ustekinumab biosimilar

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous Injection

5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO

Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America

Biocon Q4FY25 results: Consolidated net profit rises 153% to ₹344 crore

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ended March 31, 2025 aided by robust sales across business verticals. The company had reported a net profit of Rs 136 crore in the January-March period of the preceding fiscal. Total revenue rose to Rs 4,454 crore in the latest fourth quarter as compared to Rs 3,966 crore in the year-ago period, Biocon Ltd said in a statement. For the year ended March 31, 2025, the company said its net profit declined to Rs 1,013 crore as compared to Rs 1,022 crore in FY24, it added. Total revenue rose to Rs 16,470 crore in FY25 as compared to Rs 15,621 crore recorded in FY24, the company said. "The Biocon Group ended the year with a strong performance across its businesses," Biocon Group Chairperson Kiran Mazumdar-Shaw said. FY25 has been a year of consolidation and transition, she stated. "We are now on a path of accelerating growth with a commitment to innovation, digita

Stocks to Watch, May 8: Britannia, Coal India, Dabur, Voltas, RIL, L&T, PNB

Stocks to Watch on May 8, 2025: Here is a list of stocks that will be on investors' and traders' radar on Thursday, May 8, 2025

Biocon Biologics secures multiple market access coverage for Yesintek in US

Biocon Biologics' biosimilar Yesintek is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, and promises a cost-effective treatment

Syngene Q4 results: PAT down 3%, revenue from ops up 11% to ₹1,018 cr

Bains further noted that after a subdued first half, impacted by a sector-wide downturn in US biotech funding, the second half of the year showed signs of recovery

Biocon subsidiary secures permission to launch eye medicine Yesafili in US

Agreement enables company to make 'strategic entry' in ophthalmology sector in the US, it says

Biocon Biologics signs deal, gets market entry for Yesafili in US by 2026

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat several types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept). Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the US Court of Appeals for the Federal Circuit (USCAFC) and the pending litigation at the US District Court for the Northern District of West Virginia, Clarksburg Division, Biocon Biologics said in a statement. The agreement enables the company, a unit of Biocon Ltd, to launch its product in the US in the second half of 2026 or earlier in certain circumstances, it added. The terms of the settlement are confidential, it stated. "This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality ..

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

The rise in the Biocon share price came after its wholly-owned unit, Biocon Pharma, received USFDA nod for Everolimus tablets.

Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio

Jobevne works by blocking a protein called VEGF, which helps tumours grow new blood vessels

Biocon, Cipla: Nifty Pharma down 6% as US eyes possible tariffs on sector

Adding to the worries of investors, US is looking for possible tariffs on the pharmaceutical goods

Peter Bains steps down as Group CEO of Biocon, to serve Syngene's MD & CEO

Furthermore, Biocon has scheduled a board meeting on April 4 to discuss and approve fundraising for its commercial business